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 Abstract 
 Objective: Oral iron substitution has shown to be insuffi cient 
for treatment of severe iron defi ciency anemia in pregnancy. 
Ferric carboxymaltose is a new intravenous (i.v.) iron for-
mulation promising to be more effective and as safe as iron 
sucrose. We aimed to assess side effects and tolerance of fer-
ric carboxymaltose compared to i.v. iron sucrose in pregnant 
women. 
 Methods: We performed a retrospective analysis of 206 preg-
nant women who were treated either with ferric carboxymaltose 
or iron sucrose for iron-defi ciency anemia with into lerability 
to oral iron substitution, or insuffi cient hemoglobin increase 
after oral iron treatment, or need for rapid hemoglobin recon-
stitution. Primary endpoint was to evaluate the maternal safety 
and tolerability. Secondary endpoint was to assess effi cacy of 
the treatment and exclude safety concerns for the fetus. 
 Results: The incidence of drug-related adverse events was 
low and mostly mild in both groups. Mild adverse events 
occurred in 7.8 % for ferric carboxymaltose and in 10.7 % for 
iron sucrose. The mean rise of hemoglobin value was 15.4 g/L 
for ferric carboxymaltose and 11.7 g/L for iron sucrose. 
 Conclusion: Ferric carboxymaltose administration in pregnant 
women is well tolerated and is not associated with any relevant 
clinical safety concerns. Ferric carboxymaltose has a compa-
rable safety profi le to iron sucrose but offers the advantage of a 
much higher iron dosage at a time reducing the need for repeated 
applications and increasing patients ’ comfort. Ferric carboxy-
maltose is the drug of choice, if i.v. iron treatment becomes 
necessary in the second or third trimester of pregnancy. 
 Keywords:  Anemia;  ferric carboxymaltose;  hemoglobin; 
 intravenous iron therapy;  iron defi ciency;  iron sucrose;  preg-
nancy;  safety;  tolerability. 
 Introduction 
 Anemia in pregnancy is one of the most frequent problems in 
Obstetrics. The most common cause of anemia in pregnancy 
is iron defi ciency. Iron-defi ciency anemia is a serious public 
health problem with signifi cant impact on physical develop-
ment  [23, 24] . Iron defi ciency in pregnancy has been defi ned 
as low ferritin levels  [9] , and it is considered the gold stan-
dard for the diagnosis of iron-defi ciency anemia in pregnancy, 
together with hemoglobin values  [19] . 
 The clinical manifestations of anemia include skin or 
mucosal pallor, lack of energy and shortness of breath, 
fatigue, lack of concentration and decreased mental, physi-
cal, and cognitive performance all of which can present in 
different grades depending on the severity of the anemia  [2] . 
Consequences of moderate to severe anemia in pregnancy 
are susceptibility to infection and premature delivery, intra-
uterine growth restriction, and the consequences of prema-
turity: increased perinatal morbidity and mortality  [13, 21] . 
This also means that anemia at the time of the delivery results 
more often in the need for blood transfusion, increased car-
diovascular risks, longer hospital stay, and problems in the 
postpartum period like reduced lactation or postpartum mood 
disorder  [7] . For the neonate, there is a risk of reduced iron 
stores with serious consequences for their development  [11, 
12, 21] . 
 There are various possible forms of treatment for iron-
defi ciency anemia. Oral iron is the preferred route of admin-
istration for mild anemia. Treatment with iron preparations is 
used routinely in pregnancy, if iron defi ciency with or without 
anemia develops. However, oral iron supplementation often 
leads to adverse effects, such as constipation, abdominal pain, 
or sickness. If these unwarranted gastrointestinal effects arise, 
adherence to iron treatment decreases. 
 Intravenous (i.v.) iron preparations are promising, especially 
in cases of severe anemia. They provide a greater and more 
rapid iron supply than oral iron therapy without the gastroin-
testinal side effects of oral substitution and make it possible 
to avoid blood transfusion with associated risks  [16] . To date, 
few studies have focused on the use of i.v. iron and its side 
effects and safety in pregnant women. Iron sucrose has been 
used for years for i.v. treatment of iron defi ciency in pregnant 
women after the fi rst trimester. However, its use is limited to 
low dose due to local and systemic side effects in higher doses. 
Recently, ferric carboxymaltose has been introduced. This iron 
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preparation can be used intravenously in high doses with up 
to 1000 mg infused in 15 min and low risk of side effects. 
We have previously shown that ferric carboxymaltose does not 
cross the placental barrier in an  in vitro dual perfusion model 
(15), and its use is approved in the second and third trimesters 
of pregnancy. However, no published data are available con-
cerning the clinical use of ferric carboxymaltose use in preg-
nant women. The aim of our study was, therefore, to compare 
i.v. ferric carboxymaltose with i.v. iron sucrose during preg-
nancy regarding the tolerability and safety profi le. 
 Methods 
 We performed a retrospective observational study to analyze the 
tolerability and effi cacy of i.v. iron therapy in pregnancy. Data were 
obtained from the maternity units in the University Hospitals of 
Berne and Geneva in Switzerland. The study was approved by the 
local ethics committees of the respective institutions. 
 All pregnant women who received i.v. ferric carboxymaltose since 
the approval of this new drug in Switzerland in February 2008 were 
eligible for entry into the study. The comparison group was formed 
by a group of equal number of pregnant women who were treated 
with i.v. iron sucrose, before ferric carboxymaltose was introduced 
on the market (i.e., before February 2008). 
 Laboratory testing, indication, and prescription of the iron sub-
stitution treatment were determined by the attending medical team. 
Inclusion criteria for i.v. iron treatment at both centers were accord-
ing to specifi c local maternity guidelines on diagnosis and treatment 
of anemia in pregnancy as well as to specifi c national guidance  [7] . 
These included the following: pregnancy, clinically relevant severe 
iron-defi ciency anemia, intolerance to oral iron substitution, failure 
of hemoglobin increase after oral iron treatment, or need for rapid 
hemoglobin- reconstitution. Patients with early pregnancy (before 
13 weeks gestation) were excluded. 
 Patients were identifi ed by searching digital records of the hospi-
tals. Baseline data were collected on maternal age and weight, ges-
tational age, results from peripheral blood counts before and after 
treatment, serum ferritin prior to treatment, adverse events during i.v. 
iron treatment, and pregnancy outcomes. i.v. iron was administered 
by nurses or midwives, and they were instructed to document the 
procedure and any side effects during and after i.v. administration. 
 The primary endpoint of this study was to evaluate the maternal 
tolerability and side effects of ferric carboxymaltose compared to 
iron sucrose being used for treatment of iron-defi ciency anemia in 
the second and third trimesters of pregnancy. Secondary endpoints 
included effi cacy of the treatment and signs for concern regarding the 
fetal safety. For the effi cacy analysis, only women with ferritin lev-
els  ≤ 30  μ g/L were included as a ferritin level  ≤ 30  μ g/L is required 
for the diagnosis of iron-defi ciency anemia. 
 Statistical analysis was performed using Windows Excel 
Calculation and Graphpad InStat (GraphPad Software, Inc., La Jolla, 
CA, USA). Continuous variables were compared using Student ’ s  t -
test; categorical variables were compared using  χ 2 -test or Fisher ’ s 
exact test where applicable. For all analyses, P-values  < 0.05 were 
considered statistically signifi cant. 
 Results 
 A total of 206 pregnant women were included in the study; 
103 received ferric carboxymaltose since February 2008, 
and 103 received iron sucrose between 2005 and 2007. 
Demographic characteristics and basic data are summarized 
in Table  1 . While demographic data did not show any sig-
nifi cant difference between groups, there was a statistically 
highly signifi cant difference regarding the administered iron 
dose and the repeated application. Patients in the ferric car-
boxymaltose group received, in average, the double dose of 
iron weekly (Table 1). More patients in the iron sucrose group 
received repetitive doses of iron intravenously. These differ-
ences correspond to the recommended treatment schemes of 
ferric carboxymaltose and iron sucrose, respectively; ferric 
carboxymaltose can be administered in much higher single 
doses than iron sucrose. 
 Side effects, tolerance 
 As summarized in Table  2 , patients treated with ferric car-
boxymaltose had fewer side effects than those receiving iron 
sucrose, but the difference did not reach statistical signifi -
cance. Mild local reactions at the injection site were reported 
by three patients after receiving ferric carboxymaltose. One 
reported local pain and swelling at the injection site, the two 
other patients reported a rush on the arms and legs. Mild sys-
temic reactions were reported by fi ve patients, three patients 
had a transient hypotension (systolic blood pressure  < 100 
mm Hg), one of them also described dizziness, and another 
one had headache. Concerning the hypotension, no medical 
intervention was required, and their blood pressures normali-
zed spontaneously. In the group receiving iron sucrose, a total 
of 11 adverse events were reported, 8 mild systemic reactions 
and 3 local reactions. The systemic reactions consisted in fi ve 
cases of mild hypotension with dizziness and headache, two 
cases of heart palpitation during/after the infusion, and one 
case of nausea. Figure  1 graphically depicts the differences 
between groups. 
 Fetal safety and neonatal outcome 
 Among women treated with ferric carboxymaltose, 60.2 % 
were hospitalized due to high-risk pregnancy, such as preterm 
labor, intrauterine growth restriction, or abnormal placenta-
tion. They were closely monitored with daily CTG, Doppler 
ultrasound twice a week, and biophysical profi le every 
2 weeks. No signs of negative effects of the i.v. iron treatment 
were detected on the fetus. 
 Of all women treated with ferric carboxymaltose, 77 % 
delivered healthy babies at term. Twenty-three percent of the 
women delivered preterm babies due to complications, which 
were present before ferric carboxymaltose administration, 
related to their high-risk pregnancies. 
 Among the women treated with i.v. iron sucrose, fewer had 
high-risk pregnancies, and fewer had inpatient treatment. This 
explains the difference in neonatal outcome: in this group, 91, 
8 % delivered healthy babies at term, 8, 2 % had preterm deli-
very, all of them due to high-risk pregnancy situations other 
than anemia. Among the women treated with i.v. iron sucrose, 
16.5 % had been treated as inpatients due to their high-risk 
situation. 
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 The gestational age at birth between both groups was sta-
tistically different: ferric carboxymaltose group (38.4 ± 3.26) 
vs. iron sucrose group (39.6 ± 2.65), P = 0.009. Therefore, 
more babies in the ferric carboxymaltose group were trans-
ferred to NICU due to prematurity. There were no differences 
between both groups in the APGAR scores and umbilical 
cord pH values. There was no statistically signifi cant differ-
ence between both groups regarding intrauterine deaths and 
neonatal deaths. 
 Effi cacy of i.v. iron treatment 
 In the group treated with ferric carboxymaltose, 85 % had 
a ferritin level  ≤ 30  μ g/L. In the group treated with iron 
sucrose, 77 % had a ferritin level  ≤ 30  μ g/L. Table  3 shows 
mean hemoglobin values in both groups before and after i.v. 
iron treatment. Women treated with iron sucrose received 
400 mg iron per week in two infusions, 48 h apart. Forty-
seven patients received repeated applications up to eight 
times. The maximum dose of 500 mg/week was never 
exceeded. For the mean, every woman treated with iron 
sucrose was given 6 mg iron sucrose/kg body weight per 
week (Table 1). 
 Table 1  Demographic characteristics and base data. 
Ferric carboxymaltose
(n = 103)
Iron sucrose
(n = 103)
P-value
Mean (range) Mean (range)
Age (years)  29.0 (16 – 45)  29.9 (17 – 43)  0.484
Maternal weight (kg)  73.1 (46 – 119)  69.3 (45 – 119)  0.167
Gestational age (weeks)  30.7 (13 – 40)  30.6 (8 – 39)  0.883
Mean ± SD Mean ± SD
Hemoglobin (g/L)**  97.4 ± 9.9  95.4 ± 4.9  0.199
MCH (pg)  27 ± 3.6  26 ± 4.1  0.503
MCV (fL)  82 ± 8.6  81 ± 10.2  0.282
Ferritin ( μ g/L)**  12.8 ± 29.1  7 ± 5.65  0.483
CRP (mg/L)  8 ± 14.12  19 ± 38.5  0.066
Vitamin B12 ( μ g/L) 165 ± 112 206 ± 102  0.296
Folic acid ( μ g/mL)  16 ± 9.8  21 ± 9.4  0.266
Iron dose (mg/kg/week)  13 ± 3.1  6 ± 0.9  < 0.001*
Iron dose (mg/pt/week) 933 ± 173.2 402 ± 24.2  < 0.001*
Subjects receiving repeated 
applications ( > 1 × )
 13  47  < 0.001*
Follow-up interval (days) 28.4 ± 31.2  41.2 ± 27.3  0.0136*
(1 – 158) (2 – 140)
 *Statistically signifi cant.
**Value prior to fi rst drug administration. 
 Table 2  Local and systemic adverse events. 
Ferric carboxymaltose Iron sucrose P-value
(n = 103) (n = 103)
Local reactions 3 (2.9 % )   3 (2.9 % ) 1.000
Systemic reactions 5 (4.9 % )   8 (7.8 % ) 0.568
Adverse events total 8 (7.8 % ) 11 (10.7 % ) 0.631
0%
5%
10%
15%
Local Systemic Total
Adverse events
Ferric carboxymaltose
Iron sucrose
 Figure 1  Local and systemic adverse events. 
 Women treated with ferric carboxymaltose received up to 
1300 mg iron per week. On average, 13 mg/kg body weight 
per week was given. This corresponds to more than double 
the amount of iron that was administered with iron sucrose. 
Only 13 patients had one more repetitive application. Most 
patients just got 1000 mg ferric carboxymaltose i.v. In two 
women with body weights below 60 kg, the recommended 
maximal ferric carboxymaltose dose of 15 mg/kg body 
weight was exceeded with no associated noticeable negative 
effect. 
 The mean hemoglobin rise in the group receiving ferric car-
boxymaltose was 15.4 g/L and 11.7 g/L in the group receiving 
iron sucrose. The mean follow-up time was different in both 
groups after i.v. iron administration. The mean follow-up for 
the group treated with ferric carboxymaltose was 28.4 days 
and 41.2 days for the group treated with iron sucrose. This 
difference is statistically signifi cant. 
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 Discussion 
 Screening for iron-defi ciency anemia in pregnancy has been 
based on the association with increased risk of preterm deli-
very and low birth weight, and maternal signs and symptoms 
of anemia. While the consequences of mild to moderate iron-
defi ciency anemia for the fetus may be overestimated  [2] , 
severe iron-defi ciency anemia leads to increase in morbidity 
of pregnant women and their children in developing as well 
as in developed countries. 
 In the majority of cases, anemia can be treated effectively 
with oral iron preparations. Many patients tolerate oral 
intake of iron supplements well; however, up to 40 % have 
side effects related to oral iron treatment. The incidence 
of adverse reactions is dose dependent. The main adverse 
effects are of gastrointestinal nature  [1, 5, 7] , the most com-
mon being constipation, diarrhea, epigastric discomfort, 
nausea, severe abdominal pain, or vomiting. These second-
ary effects can be lessened by the intake of tablets after 
meals, although this leads to a concomitant reduction of 
iron absorption. Typically, these adverse effects lead to poor 
treatment adherence especially in pregnancy when similar 
gastrointestinal complaints are often a problem prior to iron 
treatment due to the physiological changes in pregnancy. 
Intolerance to oral iron intake leads to a greater percentage 
of failure in the treatment. In addition, even with strict oral 
iron treatment adherence, there are still quite a number of 
patients who do not respond with an appropriate hemoglo-
bin increase (i.e., hemoglobin increase below 10 g/L within 
14 days)  [17] . 
 Other possible indications for i.v. iron treatment include 
the necessity of rapid increase of hemoglobin, for example, 
pregnancies in the third trimester with high-risk of peripar-
tum hemorrhage (e.g., placenta previa or placenta increta), or 
Jehovah ’ s Witnesses  [21] . 
 In these clinical situations described above, i.v. iron 
administration is indicated. A faster increase in hemoglobin, 
ferritin, and iron stores by i.v. iron therapy has been reported 
by different authors  [5, 6, 8, 10, 15, 17, 20 – 22] . 
 Severe anemia mainly occurs in developing countries 
where it has been attributed to poor nutrition and concurrent 
conditions, especially infectious diseases, such as malaria. 
These women particularly benefi t from high-dose i.v. iron 
substitution because availability of blood transfusions is very 
limited, and blood transfusions still bare certain risks. I.V. 
iron substitution in this low-resource setting seems to be a 
very good and safe alternative. 
 Side effects and tolerance 
 The tolerance and effi cacy of ferric carboxymaltose has 
been demonstrated previously in several studies for differ-
ent groups of patients with iron-defi ciency anemia  [3, 4, 7, 
8, 14, 19, 21] with similar results. Bailie GR  [3] showed in a 
review paper, including nine randomized studies with more 
than 3000 patients, that ferric carboxymaltose had a good tol-
erability and effi ciency profi le. The use of ferric carboxymalt-
ose for treatment of postpartum anemia has been extensively 
investigated  [7, 19, 21] . No safety concerns have been identi-
fi ed in breastfed infants of mothers receiving ferric carboxy-
maltose  [7] . 
 Ferric carboxymaltose is approved for use in pregnancy in 
the second and third trimesters. However, up to now, no pub-
lished data from clinical studies investigating the use of ferric 
carboxymaltose in pregnancy are available. 
 Our study shows that ferric carboxymaltose is well toler-
ated in pregnant women and has fewer or equal number of 
side effects compared to the previously used iron sucrose 
when administered in a dose double as high. The incidence of 
drug-related adverse events was low and comparable to those 
described for ferric carboxymaltose and iron sucrose in other 
studies. Registered adverse events were all classifi ed as mild 
and quickly reversible and mostly restricted to local reactions 
at the infusion site. There were no treatment-related serious 
adverse events. No anaphylactic or anaphylactoid reaction 
was detected. No venous thrombosis was registered. None of 
the adverse events required further medical intervention. 
 Fetal safety and neonatal outcome 
 Previously, an  in vitro study using a dual-placenta perfusion 
model has shown that ferric carboxymaltose does not cross 
the placental barrier to the fetal side  [15] . Though there is no 
previous published clinical data available on the use of ferric 
carboxymaltose in pregnancy and its effects on the fetus, fer-
ric carboxymaltose is approved for use in the second and third 
trimesters of pregnancy. We, therefore, have chosen to give 
ferric carboxymaltose initially in an inpatient setting to be 
able to closely monitor the pregnant women and the fetus for 
adverse reactions and negative effects. The pregnant women 
being treated as inpatients were mainly high-risk pregnancies 
due to other complications than IDA. This explains why the 
gestational age was signifi cantly higher in the iron sucrose 
group compared to the group receiving ferric carboxymaltose, 
and therefore, birth weight at delivery was also higher in the 
group of iron sucrose. Newborn intensive care unit (NICU) 
admission rate was higher in the group of newborns from 
women receiving ferric carboxymaltose due to a lower gesta-
tional age at delivery in this group with no correlation to i.v. 
iron treatment. There was no statistically signifi cant differ-
ence between both groups regarding intrauterine deaths and 
neonatal deaths. Both groups of pregnant women were het-
erogeneous, and therefore not really comparable, regarding 
 Table 3  Hemoglobin values before and after treatment. 
Mean ± SD range P-value
Ferric 
carboxymaltose
Iron 
sucrose
Hemoglobin before  98.3 ± 10.9  95.6 ± 12.1 0.1581
treatment (g/L)  77 – 125  71 – 140
Hemoglobin after 113.1 ± 12.3 110.4 ± 11.9 0.2603
treatment (g/L)  81 – 149  88 – 147
Rise in hemoglobin  15.4 ± 11.7  11.7 ± 10.0 0.0819
value (g/L)  – 5 to  43  – 4 to  43
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pregnancy complications. Nevertheless, no sign for negative 
effect on the fetus of iron infusion could be detected, although 
levels of ferritin were not determined in newborns. 
 Effi cacy 
 I.V. iron treatment indications were heterogeneous and did 
not always correspond to national recommendations. Owing 
to heterogeneity in indications for i.v. iron treatment and in 
dosage of the drugs and also regarding follow-up intervals in 
our study population, comparability of effi cacy of ferric car-
boxymaltose vs. iron sucrose is limited. Both i.v. iron prepa-
rations are effective in treating anemia in pregnancy. The 
differences between the administered amounts of iron were 
statistically signifi cant when giving ferric carboxymaltose 
and iron sucrose as well as the repetitions of the treatment 
(Table 1). These facts suggest that the larger the amount of 
iron that can be administered in the form of ferric carboxy-
maltose, the more effective the replenishment of the iron 
stores is and the more effective the correction of the anemia 
is. This, however, needs to be confi rmed in appropriately 
designed prospective studies. 
 Whether ferric carboxymaltose provides a faster and higher 
increase in hemoglobin level than iron sucrose cannot be con-
cluded from these data due to the possibility of administering 
a higher dose of iron within a shorter time period. 
 Strength of the study 
 This is the fi rst study assessing the prevalence of side effects 
and tolerability of i.v. ferric carboxymaltose treatment in preg-
nant women. Data on unwarranted side effects are reliable as 
they are prospectively collected and documented during and 
after treatment. Ferric carboxymaltose was used mainly in an 
inpatient population to ensure maximal safety, observation, 
and monitoring. 
 Limitations of the study 
 The retrospective design of the study determines the limita-
tions. Indications for i.v. iron treatment, dosages of ferric 
carboxymaltose and iron sucrose varied according to clinical 
situations. The groups were different before i.v. iron treatment 
regarding pregnancy complications, limiting interpretation of 
neonatal outcome data. Follow-up data to evaluate outcome 
was inhomogenic, and no data were available on ferritin and 
transferrin saturation after the treatment. Regarding the neo-
natal outcome, no data on the hematological status and fer-
ritin levels were available. Neither the impact of anemia on 
maternal quality of life nor the benefi ts of the treatment were 
assessed. 
 In summary, our study shows that the tolerance of ferric 
carboxymaltose in pregnancy is excellent, and prevalence of 
side effects is low, even when administered in a much higher 
iron dose compared to iron sucrose. Compared to iron sucrose, 
it offers the advantage of a much higher iron dosage at a time 
reducing the need for repeated applications and increasing 
patients ’ comfort. No relevant clinical safety concern of ferric 
carboxymaltose regarding either mother or fetus could be 
identifi ed at short and midterm. 
 In view of the limited evidence from prospective randomi-
zed trials of i.v. iron treatment in pregnancy, full consider-
ation must be given to possible benefi ts and risks. Indications 
for the use of parenteral iron should be limited to specifi c 
conditions, in which oral iron supplementation is not possible 
or fails. 
 While further research including randomized trials is 
needed  [18] , ferric carboxymaltose seems to be the drug of 
choice if i.v. iron treatment during pregnancy becomes neces-
sary in the second or third trimester. 
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